Table of Contents Author Guidelines Submit a Manuscript
Contrast Media & Molecular Imaging
Volume 2017 (2017), Article ID 7498538, 8 pages
https://doi.org/10.1155/2017/7498538
Research Article

Molecular Imaging to Predict Response to Targeted Therapies in Renal Cell Carcinoma

1IR4M, UMR 8081, Paris-Sud University, CNRS, Bâtiment 220, rue Ampère, 91405 Orsay Cedex, France
2Gustave Roussy, 114 rue Edouard Vaillant, 94805 Villejuif Cedex, France
3Service Urologie, Hôpital Bicêtre, 78 rue du Général Leclerc, 94270 Le Kremlin-Bicêtre, France
4Experimental Imaging, MRI Unit, Research Division, Guerbet, 93600 Aulnay-sous-Bois, France

Correspondence should be addressed to Ingrid Leguerney; rf.yssuorevatsug@yenreugel.dirgni

Received 9 September 2016; Revised 26 January 2017; Accepted 9 March 2017; Published 9 April 2017

Academic Editor: Anne Roivainen

Copyright © 2017 Ingrid Leguerney et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Molecular magnetic resonance imaging targeted to an endothelial integrin involved in neoangiogenesis was compared to DCE-US and immunochemistry to assess the early response of three different therapeutic agents in renal cell carcinoma. Human A498 renal cells carcinoma was subcutaneously inoculated into 24 nude mice. Mice received either phosphate-buffered saline solution, sunitinib, everolimus, or bevacizumab during 4 days. DCE-US and molecular MRI targeting αvβ3 were performed at baseline and 4 days after treatment initiation. PI, AUC, relaxation rate variations , and percentage of vessels area quantified on CD31-stained microvessels were compared. Significant decreases were observed for PI and AUC parameters measured by DCE-US for bevacizumab group as early as 4 days, whereas molecular αvβ3-targeted MRI was able to detect significant changes in both bevacizumab and everolimus groups. Percentage of CD31-stained microvessels was significantly correlated with DCE-US parameters, PI (, ) and AUC (, ). The percentage of vessel tissue area was significantly reduced () in both sunitinib and bevacizumab groups. We report an early detection of neoangiogenesis modification after induction of targeted therapies, using DCE-US or αvβ3-targeted MRI. We consider these outcomes should encourage clinical trial developments to further evaluate the potential of this molecular MRI technique.